← Back to Screener
Psyence Biomedical Ltd. Common Shares (PBM)
Price$11.30
Favorite Metrics
Price vs S&P 500 (26W)-103.36%
Price vs S&P 500 (4W)207.17%
Market Capitalization$7.77M
P/E Ratio (Annual)7.68x
All Metrics
Book Value / Share (Quarterly)$247.64
Indicated Dividend (Annual)$0.00
Cash Flow / Share (Quarterly)$-10.58
Price vs S&P 500 (YTD)-78.32%
EPS (TTM)$1612.06
10-Day Avg Trading Volume10.45M
EPS Excl Extra (TTM)$1612.06
EPS (Annual)$1631.92
ROI (Annual)15.05%
Cash / Share (Quarterly)$149.21
P/E Basic Excl Extra (TTM)30.05x
EPS Growth (5Y)143.93%
P/E Normalized (Annual)7.68x
ROA (Last FY)13.83%
EBITD / Share (TTM)$-17.47
Cash Flow / Share (Annual)$-2057.21
P/B Ratio0.65x
P/B Ratio (Quarterly)0.50x
Net Income / Employee (Annual)$0
Net Interest Coverage (TTM)-141.21x
ROA (TTM)-5.88%
EPS Incl Extra (Annual)$1631.92
Current Ratio (Annual)11.04x
Quick Ratio (Quarterly)7.82x
3-Month Avg Trading Volume1.31M
52-Week Price Return-94.76%
P/E Incl Extra (TTM)30.05x
Revenue / Employee (TTM)$0
52-Week High$468.38
EPS Excl Extra (Annual)$1631.92
26-Week Price Return-94.61%
Quick Ratio (Annual)10.61x
13-Week Price Return-74.98%
Total Debt / Equity (Annual)0.00x
Current Ratio (Quarterly)8.09x
Enterprise Value$0.619
Revenue / Employee (Annual)$0
Cash / Share (Annual)$3370.97
3-Month Return Std Dev296.39%
Net Income / Employee (TTM)$0
ROE (Last FY)15.05%
Net Interest Coverage (Annual)-92.58x
EPS Basic Excl Extra (Annual)$1631.92
Total Debt / Equity (Quarterly)0.00x
EPS Incl Extra (TTM)$1612.06
ROI (TTM)-6.35%
Revenue / Share (Annual)$0.00
Price vs S&P 500 (52W)-129.85%
P/E Ratio (TTM)30.05x
Year-to-Date Return-74.18%
5-Day Price Return172.40%
EPS Normalized (Annual)$1631.92
ROA (5Y Avg)-960.97%
Month-to-Date Return208.94%
EBITD / Share (Annual)$689.37
EPS Growth (3Y)345.96%
P/E Excl Extra (TTM)30.05x
EPS Basic Excl Extra (TTM)$1612.06
P/B Ratio (Annual)0.40x
Book Value / Share (Annual)$3693.41
Price vs S&P 500 (13W)-77.85%
Beta1.93x
Revenue / Share (TTM)$0.00
ROE (TTM)-6.35%
52-Week Low$1.92
Industry Peers — Pharmaceuticals(309)
| Symbol | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|
PBMPsyence Biomedical Ltd. Common Shares | — | — | — | 143.93% | $11.30 |
LLYEli Lilly & Co. | 13.45x | 44.70% | 83.04% | 27.59% | $919.90 |
JNJJohnson & Johnson | 5.82x | 7.87% | 67.95% | 14.90% | $230.69 |
ABBVABBVIE INC. | 5.97x | 8.57% | 71.62% | -2.88% | $203.71 |
MRKMerck & Co., Inc. | 4.51x | 1.31% | 78.55% | 21.23% | $117.10 |
AZNAstraZeneca PLC | 5.39x | 8.63% | 81.31% | 21.88% | $200.69 |
NVSNovartis AG | 4.87x | 8.91% | 75.82% | 15.26% | $150.99 |
NVONovo-Nordisk A/S | 3.74x | 6.43% | 80.98% | 20.66% | $40.46 |
ABTAbbott Laboratories | 3.71x | 6.59% | 56.50% | 8.20% | $96.00 |
PFEPfizer Inc. | 2.50x | -1.64% | 75.81% | -3.51% | $27.52 |
BMYBristol-Myers Squibb Co. | 2.52x | -0.22% | 72.63% | — | $59.13 |
About
Psyence Biomedical Ltd is a biotechnology company developing psilocybin-based treatments for mental health conditions, including psychological trauma in palliative care. The company's product candidates are advancing through clinical trials to evaluate safety and efficacy. It operates a federally licensed cultivation facility in Southern Africa to produce natural psilocybin mushrooms for export and standardized pharmaceutical processing.